Pharmaceutical formulations containing gaboxadol for therapeutic treatment
US2020246293A1
Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere's disease, tourette's syndrome, attention deficit hyperactivity disorder and addiction
US2020188365A1
Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
US2020138785A1
Use of gaboxadol, ganaxolone and allopregnanolone to treat movement disorders
CA3113644A1
Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
CA3110218A1
Use of gaboxadol in the treatment of gastrointestinal tract disorders and asthma
WO2020018779A1
Use of phenylethylidenehydrazine to treat seizure disorders, developmental disorders, neurological disorders, behavioral disorders and addiction
AU2019285298A1
Use of MIR-92a or MIR-145 in the treatment of Angelman syndrome
CA3102786A1
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
US2019350882A1
Methods of treating attention deficit hyperactivity disorder
WO2019195813A1
Use of gaboxadol in the treatment of substance use disorders
US2019298674A1
Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders
US2019247394A1
Methods of treating developmental syndromes with PDE10A inhibitors
CN112261938A
Use of (1S,3S) -3-amino-4- (difluoromethylene) cyclopentane-1-carboxylic acid and (S) -3-amino-4- (difluoromethylene) cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere 'S disease, Tourette' S syndrome, attention deficit hyperactivity disorder and addiction
AU2018392620A1
Use of hM4Di in the treatment of seizure disorders
CN111417397A
Use of MIR101 or MIR128 in the treatment of episodic disease
CA3075478A1
Use of gaboxadol in the treatment of narcolepsy
AU2018320849A1
Recombinant adeno-associated vectors
CN111201022A
Use of gaboxadol for treating diabetes and related conditions
